1. Home
  2. IMMR vs ACIU Comparison

IMMR vs ACIU Comparison

Compare IMMR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$7.35

Market Cap

215.8M

Sector

Technology

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.64

Market Cap

247.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
ACIU
Founded
1993
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
215.8M
247.6M
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
IMMR
ACIU
Price
$7.35
$2.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$13.50
$10.00
AVG Volume (30 Days)
312.3K
145.9K
Earning Date
04-13-2026
05-12-2026
Dividend Yield
5.11%
N/A
EPS Growth
N/A
N/A
EPS
0.17
N/A
Revenue
$35,013,000.00
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
$42.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$2.10
52 Week High
$8.05
$4.00

Technical Indicators

Market Signals
Indicator
IMMR
ACIU
Relative Strength Index (RSI) 48.19 48.43
Support Level $6.30 $2.52
Resistance Level $7.82 $2.68
Average True Range (ATR) 0.21 0.12
MACD -0.04 -0.03
Stochastic Oscillator 43.07 16.28

Price Performance

Historical Comparison
IMMR
ACIU

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: